Reiko
Go read about double blind placebo trials. You’ll get a better sense of what’s going on, versus reading Ihubbers here, guessing at stuff.
Transparency leads to biases, and that interferes with Scientific Trials.
BTW, Michael Frank is being VERY transparent because he doesn’t know anything about trial data.
All he is told by Pharm Olam is that “end points” are hit.
210 enrollment taking a full 14 day treatment was an end point, and was achieved just before Christmas.
42 day follow up of that first 210 would continue into Q1 2021.
I imagine that Pharm Olam paused the trial shortly until the decision was made by those at Pharm Olam about which dosage to continue with. That’s why you see additional sites added.
April 1 is first day of Q2, so hang tight, good news is coming or the trial would have been shut down by now because of missed end points.
I highly doubt that there is any unblinding of the trial until all Data is in. That means that there is no 210 news coming, but the only ones who said that 210 data was coming was from someone on this iHub board. And they always called a Catalyst.
News 
Market Data 
Discover 
